Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Prevenar 13 in healthy Indian infants with routine pediatric vaccinations
2008-003687-20Phase 3
- Sponsor
- Wyeth
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Wyeth. Primary endpoint: Percentage of subjects achieving predefined pneumococcal antibody threshold after infant series.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2008-003687-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003687-20.